Quantifying treatment value under IRA: a case study of rifaximin for the treatment of overt hepatic encephalopathy using QALY and non-QALY measures
Rifaximin is a cost-effective treatment for preventing OHE recurrence in adults using QALY and non-QALY health benefit measures.
Authors
- Olamide Olujohungbe
- Leonardo Passos Chaves (ORCID: https://orcid.org/0000-0002-1881-0760)
- Jason T. Shafrin (ORCID: https://orcid.org/0000-0001-8444-5979)
- Srinivasan Muthukrishnan (ORCID: https://orcid.org/0009-0008-9348-5778)
- Shanshan Wang (ORCID: https://orcid.org/0000-0002-3424-9934)
- Aditi Chaudhary (ORCID: https://orcid.org/0009-0009-5784-1576)
Institutions
- University of Southern California (US)
- California Southern University (US)
- Bausch Health (United States) (US)
- Bausch Health (Canada) (CA)
- LEK Consulting (United States) (US)
Publication Details
- Journal
- Journal of Medical Economics
- Published
- 2025-11-26
- DOI
- https://doi.org/10.1080/13696998.2025.2587415
- Primary Topic
- Liver Disease and Transplantation
- Type
- article
- Field-Weighted Citation Impact
- 0.00